Overview

Daratumumab in Subjects With Relapsed/Refractory Acute Myelogenous Leukemia or High-Risk Myelodysplastic Syndrome

Status:
Not yet recruiting

Trial end date:
0000-00-00

Target enrollment:

Participant gender:

Summary

The goal of this clinical research study is to learn if daratumumab can help to control acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (MDS) that is refractory (does not respond to treatment) or relapsed (comes back after being treated). The safety of this drug will also be studied.

Phase:

Phase 2

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborator:

Janssen Scientific Affairs, LLC

Treatments:

Antibodies, Monoclonal
Daratumumab